🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Ensign Group's Inorganic Growth Impresses, Debt Level Hurts

Published 08/31/2017, 08:54 AM
Updated 07/09/2023, 06:31 AM
US500
-
ELV
-
AET
-
AMED
-
ENSG
-

The Ensign Group, Inc. (NASDAQ:ENSG) boasts a strong inorganic growth story driven by its expertise in acquiring real estate or leasing post-acute care operations and transforming them into market leaders. These initiatives position the company well for robust organic growth.

The company’s revenues have been growing since 2012. Apart from inorganic growth, the consistent strong performance by the Transitional & Skilled Services segment has also aided its top-line growth. The trend continued in the first half of 2017 as well.

Ensign Group’s solid financial health also paves the way for several growth oriented capital deployment strategies. The company has been paying dividends since 2002 and has increased its payout annually for the past 14 years. Frequent share repurchases and dividends payments have helped it retain investors’ confidence in this stock. In the last one year, its shares have gained 5% while the industry declined nearly 27%.

However, Ensign Group’s long-term debt level has been rising since 2011. The trend continued in first-half 2017 as well. This rising level of debt not only raises financial risks but also increases interest expenses which, in turn, hurt the margins.

Rising level of operating expenses also leads to increase in total expenses. This severely affects the company’s bottom line.

Ensign Group’s valuation looks expensive at the current level. Looking at the company’s trailing 12-month price-to-sales (P/S) ratio, investors may not want to pay any further premium. It currently has a one-year P/S ratio of 0.6, which is above the industry average of 0.2.

Zacks Rank and Key Picks

Ensign Group currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Investors interested in the medical sector can consider stocks like Aetna, Inc (NYSE:AET) , Anthem, Inc. (NYSE:ANTM) and Amedisys Inc (NASDAQ:AMED) . All the three stocks carry a Zacks Rank #2 (Buy).

Aetna’s earnings surpassed expectations in each of the last four quarters with an average beat of nearly 19%.

Anthem delivered positive surprises in three of the last four quarters with an average beat of 8.6%.

Amedisys delivered positive surprises in three of the last four quarters with an average beat of 7.2%

One Simple Trading Idea

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.

Learn more >>



Aetna Inc. (AET): Free Stock Analysis Report

Anthem, Inc. (ANTM): Free Stock Analysis Report

The Ensign Group, Inc. (ENSG): Free Stock Analysis Report

Amedisys Inc (AMED): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.